Phase 2 trial of cixutumumab in children, adolescents, and young adults with refractory solid tumors: A report from the Children's Oncology Group

Pediatric Blood and Cancer

Volumn 61, Issue 3, 2014, Pages 452-456

  Weigel, Brenda ^a   Malempati, Suman ^b   Reid, Joel M ^c   Voss, Stephan D ^d   Cho, Steven Y ^e   Chen, Helen X ^f   Krailo, Mark ^g   Villaluna, Doojduen ^h   Adamson, Peter C ⁱ   Blaney, Susan M ^j  

^a UNIVERSITY OF MINNESOTA   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c MAYO CLINIC   (United States)

^d BOSTON CHILDREN S HOSPITAL   (United States)

^e JOHNS HOPKINS HOSPITAL   (United States)

^f NATIONAL CANCER INSTITUTE   (United States)

^g UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^h CHILDREN S ONCOLOGY GROUP   (United States)

ⁱ CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^j BAYLOR COLLEGE OF MEDICINE   (United States)

more..

Author keywords

Insulin like growth factor I receptor; Investigational agents; Monoclonal antibody; Pediatric cancer

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; C PEPTIDE; CIXUTUMUMAB; HUMAN GROWTH HORMONE; INSULIN; SOMATOMEDIN B; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR;

ADOLESCENT; ADRENAL CORTEX CARCINOMA; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANAPHYLAXIS; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD TOXICITY; BODY WEIGHT DISORDER; CHILD; CHILDHOOD CANCER; COUGHING; DEHYDRATION; DIARRHEA; DRUG EFFICACY; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; EWING SARCOMA; FATIGUE; FEMALE; HEADACHE; HEPATOBLASTOMA; HUMAN; HYPERBILIRUBINEMIA; HYPERGLYCEMIA; HYPERTRIGLYCERIDEMIA; HYPOALBUMINEMIA; HYPOPHOSPHATEMIA; INFECTION; INFESTATION; LEUKOPENIA; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHROBLASTOMA; NEUROBLASTOMA; NEUTROPENIA; ORAL MUCOSITIS; OSTEOSARCOMA; PHASE 2 CLINICAL TRIAL; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEINURIA; PRURITUS; RECOMMENDED DRUG DOSE; RETINOBLASTOMA; RHABDOMYOSARCOMA; SCHOOL CHILD; SOLID TUMOR; STOMATITIS; SYNOVIAL SARCOMA; THROMBOCYTOPENIA; TREATMENT RESPONSE; TUMOR RECURRENCE; UNSPECIFIED SIDE EFFECT; VOMITING; YOUNG ADULT;

INSULIN-LIKE GROWTH FACTOR-I RECEPTOR; INVESTIGATIONAL AGENTS; MONOCLONAL ANTIBODY; PEDIATRIC CANCER;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE; NEOPLASMS; RECEPTOR, IGF TYPE 1; RECURRENCE; YOUNG ADULT;

EID: 84892502971     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24605     Document Type: Article

References (34)

1. Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 2008; 8:915-928.
2. Ayalon D, Glaser T, Werner H. Transcriptional regulation of IGF-I receptor gene expression by the PAX3-FKHR oncoprotein. Growth Horm IGF Res 2001; 11:289-297.
3. El-Badry OM, Minniti C, Kohn EC, et al. Insulin-like growth factor II acts as an autocrine growth and motility factor in human rhabdomyosarcoma tumors. Cell Growth Differ 1990; 1:325-331.
4. MacEwen EG, Pastor J, Kutzke J, et al. IGF-1 receptor contributes to the malignant phenotype in human and canine osteosarcoma. J Cell Biochem 2004; 92:77-91.
5. El-Badry OM, Romanus JA, Helman LJ, et al. Autonomous growth of a human neuroblastoma cell line is mediated by insulin-like growth factor II. J Clin Invest 1989; 84:829-839.
6. Toretsky JA, Kalebic T, Blakesley V, et al. The insulin-like growth factor-I receptor is required for EWS/FLI-1 transformation of fibroblasts. J Biol Chem 1997; 272:30822-30827.
7. Werner H, Re GG, Drummond IA, et al. Increased expression of the insulin-like growth factor I receptor gene, IGF1R, in Wilms tumor is correlated with modulation of IGF1R promoter activity by the WT1 Wilms tumor gene product. Proc Natl Acad Sci USA 1993; 90:5828-5832.
8. LeRoith D, Werner H, Beitner-Johnson D, et al. Molecular and cellular aspects of the insulin-like growth factor I receptor. Endocr Rev 1995; 16:143-163.
9. LeRoith D, Roberts CT, Jr. The insulin-like growth factor system and cancer. Cancer Lett 2003; 195:127-137.
10. Scotlandi K, Manara MC, Nicoletti G, et al. Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors. Cancer Res 2005; 65:3868-3876.
11. Tanno B, Mancini C, Vitali R, et al. Down-regulation of insulin-like growth factor I receptor activity by NVP-AEW541 has an antitumor effect on neuroblastoma cells in vitro and in vivo. Clin Cancer Res 2006; 12:6772-6780.
12. Gansler T, Furlanetto R, Gramling TS, et al. Antibody to type I insulinlike growth factor receptor inhibits growth of Wilms' tumor in culture and in athymic mice. Am J Pathol 1989; 135:961-966.
13. Geoeger B, Daudigeous E, Debussche LR, et al. The anti insulin-like growth factor I receptor (IGF1-R) antibody AVE1642 exhibits anti-tumor activity against neuroblastoma cell lines and xenografts. Proc Am Assoc Cancer Res 2006; 47:1222.
14. Maloney EK, McLaughlin JL, Dagdigian NE, et al. An anti-insulin-like growth factor I receptor antibody that is a potent inhibitor of cancer cell proliferation. Cancer Res 2003; 63:5073-5083.
15. Benini S, Manara MC, Baldini N, et al. Inhibition of insulin-like growth factor I receptor increases the antitumor activity of doxorubicin and vincristine against Ewing's sarcoma cells. Clin Cancer Res 2001; 7:1790-1797.
16. Burtrum D, Zhu Z, Lu D, et al. A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo. Cancer Res 2003; 63:8912-8921.
17. Sachdev D, Singh R, Fujita-Yamaguchi Y, et al. Down-regulation of insulin receptor by antibodies against the type I insulin-like growth factor receptor: Implications for anti-insulin-like growth factor therapy in breast cancer. Cancer Res 2006; 66:2391-2402.
18. Rowinsky EK, Youssoufian H, Tonra JR, et al. IMC-A12, a human IgG1 monoclonal antibody to the insulin-like growth factor I receptor. Clin Cancer Res 2007; 13:5549s-5555s.
19. Wu JD, Haugk K, Coleman I, et al. Combined in vivo effect of A12, a type 1 insulin-like growth factor receptor antibody, and docetaxel against prostate cancer tumors. Clin Cancer Res 2006; 12:6153-6160.
20. Wu KD, Zhou L, Burtrum D, et al. Antibody targeting of the insulin-like growth factor I receptor enhances the anti-tumor response of multiple myeloma to chemotherapy through inhibition of tumor proliferation and angiogenesis. Cancer Immunol Immunother 2007; 56:343-357.
21. Allen GW, Saba C, Armstrong EA, et al. Insulin-like growth factor-I receptor signaling blockade combined with radiation. Cancer Res 2007; 67:1155-1162.
22. Wang Z, Chakravarty G, Kim S, et al. Growth-inhibitory effects of human anti-insulin-like growth factor-I receptor antibody (A12) in an orthotopic nude mouse model of anaplastic thyroid carcinoma. Clin Cancer Res 2006; 12:4755-4765.
23. Kolb EA, Morton C, Gorlick R, et al. Initial testing of a monoclonal antibody (IMC-A12) against IGF-1R by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer 2010; 54:921-926.
24. Higano CS, Yu EY, Whiting SH, et al. A phase I, first in man study of weekly IMC-A12, a fully human insulin like growth factor-I receptor IgG1 monocolonal antibody, in patients with advanced solid tumors. J Clin Oncol 2007; 25:3505.
25. Rothenberg ML, Poplin E, Sandler AB, et al. Phase I dose-escalation study of the anti-IGF-IR recombinant human IgG1 monoclonal antibody (Mab) IMC-A12, administered every other week to patients with advanced solid tumors, Presented at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, San Francisco (CA), 2007.
26. Malempati S, Weigel BJ, Ingle AM, et al. Phase I/II trial and pharmacokinetic study of cixutumumab in pediatric patients with refractory solid tumors and Ewing Sarcoma: A report from the Children's Oncology Group. J Clin Oncol 2011; 30:256-262.
27. Jung SH, Kim KM. On the estimation of the binomial probability in multistage clinical trials. Stat Med 2004; 23:881-896.
28. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205-216.
29. 123I-MIBG whole body scan scoring method-Application to the prediction of the response of metastases to induction chemotherapy in stage IV neuroblastoma. Eur J Cancer 1995; 31A:256-261.
30. Olmos D, Postel-Vinay S, Molife LR, et al. Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751, 871) in patients with sarcoma and Ewing's sarcoma: A phase 1 expansion cohort study. Lancet Oncol 2010; 11:129-135.
31. Pappo AS, Patel S, Crowley J, et al. Activity of R1507, a monoclonal antibody to the insulin-like growth factor-1 receptor (IGF1R), in patients (pts) with recurrent or refractory Ewing's sarcoma family of tumors (ESFT): Results of a phase II SARC study. J Clin Oncol 2010; 28: abstr 10000.
32. Shang Y, Mao Y, Batson J, et al. Antixenograft tumor activity of a humanized anti-insulin-like growth factor-I receptor monoclonal antibody is associated with decreased AKT activation and glucose uptake. Mol Cancer Ther 2008; 7:2599-2608.
33. Shin DH, Min HY, El-Naggar AK, et al. Akt/mTOR counteract the antitumor activities of cixutumumab, an anti-insulin-like growth factor I receptor monoclonal antibody. Mol Cancer Ther 2011; 10:2437-2448.
34. Kolb EA, Gorlick R, Maris JM, et al. Combination testing (Stage 2) of the anti-IGF-1 receptor antibody IMC-A12 with rapamycin by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer 2012; 58:729-735.